Ikaria to in-license worldwide rights to investigational portofolio from Fibrex Medical

11-Aug-2009 - USA

Ikaria Holdings, Inc. and Fibrex Medical, Inc. announced that Ikaria has entered into an agreement under which Ikaria has acquired the exclusive worldwide license to Fibrex Medical’s portfolio of investigational compounds for a range of critical care conditions.

The investigational compounds, which are known as FX06, FX201, and FX107, are fibrin-derived peptides that bind to vascular endothelial cells, preserving endothelial barrier function and preventing tissue injury. These novel peptides, which are modified fragments of naturally occurring proteins, are being developed to augment the body’s natural protective mechanisms by preventing vascular leakage, leukocyte transmigration, and capillary vasoconstriction. The compelling mechanisms of action of these compounds, which have demonstrated biological activity in a multitude of animal disease models, hold great promise for exploration in a multitude of critical care conditions in which they play important pathogenic roles.

Through Phase I and II human trials, as well as through animal disease models, FX06 has shown evidence of a well characterized safety profile and mechanism of action, offering significant promise for many critical care conditions which Ikaria is targeting in its research & development efforts. FX107 and FX201 provide the same clinical promise, although with modified pharmacokinetic profiles.

Fibrex Medical will receive upfront and milestone payments, as well as royalties on net sales. Ikaria will be responsible for pre-clinical and clinical development activities, as well as for commercialization.

https://www.bionity.com/en/news/104585/ikaria-to-in-license-worldwide-rights-to-investigational-portofolio-from-fibrex-medical.html